Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II dose-ranging trial of a COVID-19 mRNA vaccine in healthy adults aged 18-59 years
ChiCTR2100041855Phase 2Recruiting
- Sponsor
- Walvax Biotechnology Co., Ltd.
- Start
- Jan 2021
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of RH109 in coronavirus disease 2019 (COVID-19) (4 arms), sponsored by Walvax Biotechnology Co., Ltd. Primary endpoints: IgG antibody and Neutralizing antibody. Started Jan 2021; status: recruiting.
02
Drugs
RH109
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on ChiCTR2100041855.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100041855.